Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 34 min ago
Peer-reviewedCC BY 4.0Frontiers in Endocrinology

Systemic inflammatory markers after GLP-1 receptor agonist versus DPP-4 inhibitor initiation in type 2 diabetes: an overlap-weighted active-comparator cohort study

  1. 1Department of Epidemiology, Faculty of Health Sciences, University of Debrecen
  2. 2Division of Metabolic Diseases, Department of Internal Medicine, Faculty of Medicine, University of Debrecen

Abstract

Background: Glucagon-like peptide-1 receptor agonists may influence systemic inflammation beyond their glucose-lowering effects, but direct comparative evidence against other incretin-based therapies remains limited.

Methods: We conducted a retrospective active-comparator, new-user cohort study using routinely collected electronic health-record data from the Clinical Center of the University of Debrecen, Hungary. Patients with type 2 diabetes initiating a glucagon-like peptide-1 receptor agonist or a dipeptidyl peptidase-4 inhibitor between January 2001 and December 2024 after a 12-month washout were included. Baseline markers were summarized during months −12 to −1 and follow-up markers during months 4–12. The follow-up window was selected to reduce the influence of very early post-initiation testing while allowing assessment of a sustained biomarker difference. Propensity-score overlap weighting was used to balance demographic, metabolic, renal, cardiovascular, medication, and healthcare-observation characteristics.

Results: The propensity-score cohort included 1,973 patients, including 1,322 glucagon-like peptide-1 receptor agonist and 651 dipeptidyl peptidase-4 inhibitor initiators; 838 had paired C-reactive protein measurements. The adjusted geometric mean ratio for follow-up C-reactive protein was 0.80 (95% confidence interval, 0.66–0.97; P = 0.024). The neutrophil-to-lymphocyte ratio was also lower (adjusted ratio, 0.92; 95% confidence interval, 0.87–0.97; P = 0.003; q=0.007), whereas platelet count was higher by 12.12×10 ⁹ /L (95% confidence interval, 4.65–19.59; P = 0.001; q=0.007). The C-reactive protein estimate remained similar after upper-tail winsorization, propensity-score re-estimation within the paired-CRP cohort, and patient-level bootstrap re-estimation of the propensity score. Restriction to patients with baseline CRP <10 mg/L yielded a directionally similar but less precise estimate, whereas stabilized inverse-probability-of-treatment weighting did not statistically support the association.

Conclusion: GLP-1 receptor agonist initiation was associated with lower follow-up CRP and NLR than DPP-4 inhibitor initiation among patients with available paired measurements in the propensity-score overlap population. However, the CRP association was attenuated in the 12-month survivor-restricted analysis and varied across other sensitivity analyses. Residual confounding by adiposity, treatment-associated weight changes, and selection related to survival and laboratory availability limit causal interpretation. The findings should be considered exploratory comparative biomarker associations rather than evidence of a direct or weight-independent anti-inflammatory effect.

Related

  1. Associations of mortality and sepsis after GLP-1 receptor agonist initiation versus SGLT2 inhibitor or metformin initiation in people with HIV, overweight or obesity, and type 2 diabetes: A target trial emulation
    Yu-Nan Huang, Pei-Yun Li, Kai-Wen Liu +6
    Therapeutic Advances in Endocrinology and MetabolismPeer-reviewedCC BY-NC 4.0Full textEndocrinology & metabolismPMC
  2. Incidence and predictors of urinary tract infections after sodium-glucose cotransporter 2 inhibitor initiation in older adults hospitalized for heart failure
    Jean-Baptiste Robiaud, Arthur Leroy-Mobeche, Gilles Berrut +6
    Archives of cardiovascular diseasesPeer-reviewedCC BY 4.0Full textEpidemiology & public healthHAL
  3. Clinical Comparator Dependence of Inflammatory and Hematologic Biomarker Discrimination for Sepsis: A Matched Retrospective Study Using MIMIC-IV Emergency Department Data
    Salvador Sánchez-Vela, Jorge Martín Llaca-Díaz, Erik Alejandro Díaz-Chuc +2
    Journal of Clinical MedicinePeer-reviewedCC BY 4.0General medicineCrossref
  4. Divergent Eosinophilic and Paradoxical Inflammatory Adverse-Event Signatures Across Five Type 2 Asthma Biologics: A FAERS Active-Comparator Disproportionality Analysis
    A. C. Iancu, M. Kobtan, N. Soliman +1
    medRxivPreprintCC BY-NC-NDFull textPharmacology & toxicologymedRxiv
  5. GLP-1 receptor agonist initiation and newly recorded ankylosing spondylitis diagnoses in type 2 diabetes: a target trial emulation
    Yu-Chen Lu, Tzu-Hao Li, Ya-Fang Liu +1
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textEndocrinology & metabolismCrossref
BibTeX
@article{nagy2026systemic,
  title = {{Systemic inflammatory markers after GLP-1 receptor agonist versus DPP-4 inhibitor initiation in type 2 diabetes: an overlap-weighted active-comparator cohort study}},
  author = {Attila Nagy and Amr Sayed Ghanem and Battamir Ulambayar and Vivien Jendrek and Ferenc Sztanek},
  journal = {Frontiers in Endocrinology},
  year = {2026},
  month = nov,
  doi = {10.3389/fendo.2026.1959709},
  url = {https://www.frontiersin.org/articles/10.3389/fendo.2026.1959709/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Systemic inflammatory markers after GLP-1 receptor agonist versus DPP-4 inhibitor initiation in type 2 diabetes: an overlap-weighted active-comparator cohort study
AU  - Attila Nagy
AU  - Amr Sayed Ghanem
AU  - Battamir Ulambayar
AU  - Vivien Jendrek
AU  - Ferenc Sztanek
PY  - 2026
DA  - 2026/11/16
JO  - Frontiers in Endocrinology
DO  - 10.3389/fendo.2026.1959709
UR  - https://www.frontiersin.org/articles/10.3389/fendo.2026.1959709/full
AB  - Background: Glucagon-like peptide-1 receptor agonists may influence systemic inflammation beyond their glucose-lowering effects, but direct comparative evidence against other incretin-based therapies remains limited.  Methods: We conducted a retrospective active-comparator, new-user cohort study using routinely collected electronic health-record data from the Clinical Center of the University of Debrecen, Hungary. Patients with type 2 diabetes initiating a glucagon-like peptide-1 receptor agonist or a dipeptidyl peptidase-4 inhibitor between January 2001 and December 2024 after a 12-month washout were included. Baseline markers were summarized during months −12 to −1 and follow-up markers during months 4–12. The follow-up window was selected to reduce the influence of very early post-initiation testing while allowing assessment of a sustained biomarker difference. Propensity-score overlap weighting was used to balance demographic, metabolic, renal, cardiovascular, medication, and healthcare-observation characteristics.  Results: The propensity-score cohort included 1,973 patients, including 1,322 glucagon-like peptide-1 receptor agonist and 651 dipeptidyl peptidase-4 inhibitor initiators; 838 had paired C-reactive protein measurements. The adjusted geometric mean ratio for follow-up C-reactive protein was 0.80 (95% confidence interval, 0.66–0.97; P = 0.024). The neutrophil-to-lymphocyte ratio was also lower (adjusted ratio, 0.92; 95% confidence interval, 0.87–0.97; P = 0.003; q=0.007), whereas platelet count was higher by 12.12×10 ⁹ /L (95% confidence interval, 4.65–19.59; P = 0.001; q=0.007). The C-reactive protein estimate remained similar after upper-tail winsorization, propensity-score re-estimation within the paired-CRP cohort, and patient-level bootstrap re-estimation of the propensity score. Restriction to patients with baseline CRP <10 mg/L yielded a directionally similar but less precise estimate, whereas stabilized inverse-probability-of-treatment weighting did not statistically support the association.  Conclusion: GLP-1 receptor agonist initiation was associated with lower follow-up CRP and NLR than DPP-4 inhibitor initiation among patients with available paired measurements in the propensity-score overlap population. However, the CRP association was attenuated in the 12-month survivor-restricted analysis and varied across other sensitivity analyses. Residual confounding by adiposity, treatment-associated weight changes, and selection related to survival and laboratory availability limit causal interpretation. The findings should be considered exploratory comparative biomarker associations rather than evidence of a direct or weight-independent anti-inflammatory effect.
SN  - 1664-2392
ER  -